Here you will find a host of content all about antibody drug conjugates, from articles, to exclusive interviews, and much more.
If you have anything you would like us to share in the World ADC Content Library, please contact us at firstname.lastname@example.org
Interview with Dr. Mark Wright, Site Lead, Pirimal Pharma Soloutions
SKAN: ADCs: Requirements in terms of
|Quantitative Analysis of an Antibody Drug Conjugate using MSIA D.A.R.T.‘S Technology, an Integral Part of the Universal Ligand Binding Mass Spectrometric Immunoassay (LB-MSIA) Workflow
|Thermo Fisher: Analysis of an Antibody Drug Conjugate using MSIA D.A.R.T.‘S. Technology, an Integral Part of Ligand Binding Mass Spectrometric Immunoassay (LB-MSIA)
Alain Beck, PhD Sr. Director, Antibody Physico-Chemistry Centre d’Immunologie Pierre Fabre, FR Associate Editor, mAbs, US
Cécile Combeau, Early Development Oncology, Sanofi
A Single-Use ADC Process: From Development to Clinical.
Berthold Boedeker, Biotech Development.
Andreas Pahl, Heidelberg Pharma GmbH, Ladenburg, Germany
Design, Development & Stability of ADCs: How do they differ from mAbs?
Mary E. Krause, Ph.D., Bristol-Myers Squibb
Lead author: Jian Wang, Analytical & Bioanalytical Operations, Bristol-Myers Squibb,
Gain invaluable insight on the latest news of ADCs progressing in the clinic.